Affordable Access

Publisher Website

Economic Burden of High-Responding Inhibitors in Patients with Hemophilia A in Taiwan

Yonsei Medical Journal
Yonsei University College of Medicine (KAMJE)
Publication Date
DOI: 10.3349/ymj.2013.54.2.358
  • Original Article
  • Hematology
  • Economics
  • Medicine


Purpose Hemophilia A (HA) is the most common X-linked inherited bleeding disorder. In some patients with HA, particularly those with severe HA, replacement therapy results in the production of high-responding clotting factor VIII inhibitors. The economic burden of this complication is the highest reported for a chronic disease. Our aim was to investigate the direct medical expenditure burden of high-responding inhibitors in patients with HA. Materials and Methods A retrospective study was conducted using the National Health Insurance Research Database, utilizing data covering the period of 2004-2007. Results In total, 638 males with HA, including 37 patients with high-responding inhibitors were evaluated. Over 99% of the annual median medical expenditure was attributable to the cost of clotting factor concentrates (CFCs) in patients with high-responding inhibitors. The annual median expenditure related to CFCs of the total medical care and outpatient care were US$170611 and US$141982, respectively, and were 4.6- and 4.3-fold higher in these patients during the study period, respectively. In patients with high-responding inhibitors, the median hospitalization expenditure and daily hospitalization cost with or without surgical procedures were 3.0- and 2.4-fold higher, respectively, and 4.3 and 5.6-fold higher, respectively. Conclusion Our data reveal higher medical expenditures burden for patients with HA and high-responding inhibitors in Taiwan. Future research is encouraged to evaluate the impact of this burden on patient quality of life.

There are no comments yet on this publication. Be the first to share your thoughts.